The potential role of cell cycle checkpoint inhibition in the treatment of high-grade glioma was supported by the dose-dependent radiosensitizing effect of MEK162, the MAPK-targeting agent, which downregulated the expression of WEE1, ATM, and CHK2 kinase, as well as CDK1 and CDK2. Here, ATM is linked to glioma.